Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum91545ArticlesСтатьиResearch ArticleAntiishemicheskie preparaty metabolicheskogo deystviyaАнтиишемические препараты метаболического действияSyrkinA. LСыркинА. ЛDobrovol'skiyA. VДобровольскийА. ВМосковская медицинская академия им. И.М.Сеченова15112002411VOL 4, NO11 (2002)ТОМ 4, №11 (2002)57257528122021Copyright ©; 2002, Consilium MedicumCopyright ©; 2002, ООО "Консилиум Медикум"2002Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/91545

Проводимая больным ишемической болезнью сердца (ИБС) антиангинальная терапияпризвана максимально оптимизировать соотношение между потребностями сердечной мышцы в кислороде, с одной стороны, и его доставкой к миокарду - с другой. в течение нескольких последних десятилетий предпринимались многочисленные (в целом безуспешные) попытки создать препараты, эффективно воздействующие непосредственно на ишемизированные кардиомиоциты и не оказывающие неблагоприятного воздействия на гемодинамические показатели. Триметазидин является первым (и на сегодняшний день единственным) препаратом метаболического действия, сопоставимым по антиангинальному эффекту с бета-блокаторами, блокаторами кальциевых каналов и нитратами. В многоцентровом двойном слепом плацебо-контролируемом исследовании оценивали эффективность триметазидина в форме таблеток с модифицированным высвобождением (35 мг 2 раза в сутки) у 223 больных стабильной стенокардией с положительной нагрузочной пробой, несмотря на проводимую терапию атенололом в дозе 50 мг/сут. Было показано, что продолжительность нагрузочной пробы до появления ишемической депрессии сегмента ST или ангинозной боли при лечении пролонгированным триметазидином и атенололом были достоверно больше, чем при приеме атенолола и плацебо. Важно, что эффективность проводимой терапии оценивали через 12 ч послеприема очередной таблетки триметазидна МВ.Высокая безопасность новой лекарственной формы подтверждена при проведении терапии в течение 1 года у пациентов старше 70 лет (средний возраст 84 года).Триметазидин МВ не оказывает никакого отрицательного влияния ни на клинические, ни на биологические параметры.

Lopaschuk G.D. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82 (5A): 14K-17KTaegtmeyer H., King L.M., Jones B.E. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 1998; 82 (5A): 54K-60KГлезер М.Г., Асташкин Е.И. Предуктал - новое направление в цитопротекции миокарда. Клин Геронтология 1998; 1: 1-11Шабалин А.В., Никитин Ю.П. Защита кардиомиоцита. Современное состояние и перспективы. Кардиология 1999; 29 (3): 4-10Сыркин А.Л., Долецкий А.А. Триметазидин в лечении ишемической болезни сердца. Клиническая фармакология и терапия 2001; 10 (1): 1-4Labrid C. Pertubations cellulaires induites par l'ischйmie. L'action de la trimetazidine. Presse Med 1986; 15: 1754-7Kantor P.F., Lucien A., Kozak R. et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long - chain 3-ketoacyl coenzyme A thiolase. J Circ Res 2000 86 5 580-8Mody F.V., Singh B.N., Mohiuddin I.H. et al. Trimetazidine - induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82 (5A): 42K-49KSpedding M., Tillement J.P., Morin D. et al. Medicaments interagissant avec les mitochondries: effets anti - ischemiques de la trimetazidine. Therapie 54 (5) 627-35Lopaschuk G.D. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12 Suppl 1: S8-11Sakai K., Fukushi Y., Abiko Y. Inhibitory effect of trimetazidine on utilization of myocardial glycogen during coronary ligation in dogs. Pharmacology 1986; 32 (2): 72-9de Leiris J., Boucher F. Rationale for trimetazidine administration in myocardial ischaemia - reperfusion syndrome. Eur Heart J 1993; 14 Suppl G: 34-40Maridonneau-Parini I. Effet de la trimetazidine sur les alterations membranaires induites par les radicaux libres oxygenes dans les globules rouges humains. Presse Med 1986; 15: 1762-4Perletti G., Monti E., Paracchini L.et al. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity. Arch Int Pharmacodyn Ther 302: 280-9Renaud J.F. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1 677-86Hisatome I., Ishiko R., Tanaka Y. et al. Trimetazidine inhibits Na+,K(+)-ATPase activity, and overdrive hyperpolarization in guinea - pig ventricular muscles. Eur J Pharmacol 1991; 195: 381-8Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol 1996; 28 Suppl 1: S1-10Sentex E., Sergiel J.P., Lucien A. et al. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997; 175: 153-62Grynberg A. Role des lipides membranaires dans la cytoprotection myocardique. Arch Mal Coeur Vaiss 2000; 93: 175-82Ruiz Meana M., Garcia Dorado D., Julia M. et al. Pre - treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 1996; 32: 587-92Libersa C., Honore E., Adamantidis M. et al. Effets de la trimetazidine sur un modиle d'ischemie myocardique in vitro. Presse Med 1986; 15: 1765-9Fantini E., Demaison L., Sentex E. et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58Devynck M.A., Le Quan Sang K.H., Joulin Y. et al. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol 1993; 245: 105-10Astarie-Dequeker C., Joulin Y., Devynck M.A. Inhibitory effect of trimetazidine on thrombin - induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994; 23: 401-7Belcher P.R., Drake-Holland A.J., Hynd J.W. et al. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993; 7: 149-57Willoughby S.R., Chirkov Y.Y., Kennedy J.A. et al. Inhibition of long - chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998; 207-13Williams F.M., Tanda K., Kus M. et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-33Fabiani J.N., Farah B., Vuilleminot A. et al. Chromosomal aberrations and neutrophil activation induced by reperfusion in the ischaemic human heart. Eur Heart J 1993; 14 Suppl G: 12-7Kowalski J., Pawlicki L., Baj Z. et al. Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol Merkuriusz Lek 2000; 9: 548-51Kajstura J., Liu Y., Baldini A. et al. Coronary artery constriction in rats: necrotic and apoptotic myocyte death. Am J Cardiol 1998; 82 (5A): 30K-41KGoncalves L.M. Left ventricular dysfunction and cytoprotection. Rev Port Cardiol 2000; 19 Suppl 5: V21-4Timour Q., Harpey C., Durr F. et al. Is the antianginal action of trimetazidine independent of hemodinamical changes? Cardiovasc Drugs Ther 1991; 5: 1043-4.Sellier P., Audouin P., Payen B. et al. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987; 33: 205-7Lu C., Dabrowski P., Fragasso G. et al. Effects of trimetazidine on ichemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998 Oct 1; 82: 898-901Michaelides A.P., Vyssoulis G.R., Bonoris P.E. et al. Beneficial effects of trimetazidine in men with stable angina under beta - blocker treatment. Curr Ther Res 1989; 46: 565-76Passeron J. Efficaciti de la trimetazidine dans I'angor d’effort stable de l’insuffisant coronarien chronique. Etude а double insu contre placebo. Presse Med 1986 Oct 16; 15: 1775-8Dalla-Volta S., Maraglino G., Della-Valentina P. et al. Comparison of trimetazidine with nifedipine in effort angina: a double - blind, crossover study. J Cardiovasc Drugs Ther 1990; 4 Suppl 4: 853-9Detry L., Sellier P., Pennaforte S. et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-288.Goupit P. Pharmacocinetique de la trimetazidine. Concours Med 1987; 109 Suppl, 36: 3447-51Harpey C., Clauser P., Labrid C. et al. Trimetazidine: a cellular anti - ischemic agent. Cardiovasc Drug Rev 1989; 6 (4): 292-312Edeki T.I., Johnston A., Campbell D.B. et al. An examination of the possible pharmacokinetic interaction of trimetazidine with theophylline, digoxin and antipyrine. Br J Clin Pharmacol 1989; 26: 657PSimon N., Brunet P., Roumenov D. et al. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients. Br J Clin Pharmacol 1997; 44: 591-4Wayoff M. Evaluation de l'efficacitй therapeutique de vastarel 20 mg (trimetazidine) au cours des syndromes cochlio - vestibulaires. Etude а double insu contre placebo. Ann Otolaryngol Chir Cervicofac 1984; 101: 565-9Beutter P., Guinard F., Jalbert D. et al. Etude de l'intirкt de l'administration de la trimetazidine dans le traitement des surditis brusques, en association a l'hemodilution. A propos d'une itude multicentrique. Ann Otolaryngol Chir Cervicofac 1990; 107: 345-50Martini A., De Domenico F. Trimйtazidine contre betahistine dans la maladie de Meniere. Etude а double insu. Ann Otolaryngol Chir Cervicofac 1990; 107 Suppl 1: 20-7Aubert A., Bernard C., Clauser P. et al. Effect of phenazine methosulfate on electrophysiological activity of the semicircular canal: antioxidant properties of trimetazidine. Eur J Pharmacol 1989; 174: 215-25Hauet T., Tallineau C., Goujon, J.M. et al. Efficiency of trimetazidine in renal dysfunction secondary to cold ischemia - reperfusion injury: a proposed addition to University of Wisconsin solution. Cryobiology 1998; 37: 231-44Baumert H., Goujon J.M., Richer, J.P. et al. Renoprotective effects of trimetazidine against ischemia - reperfusion injury and cold storage preservation: a preliminary study. Transplantation 1999; 68: 300-3Aussedat J., Ray A., Kay L. et al. Improvement of long - term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21: 128-35Gallet M. Efficaciti clinique de la trimetazidine dans l'angor d'effort stable. Etude controlle а double insu contre placebo. Presse Med 1986; 15: 1779-82Sellier P., Audouin P., Payen B. et al. Effets ergometriques d'une administration unique de trimetazidine. Presse Med 1986; 15: 1771-4Detry L., Leclerc P. On behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine European multicenter study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995; 76: 813-11B.Levy S. Intйrкt de l'association de la trimetazidine (vastarel 20 mg) au diltiazem (tildiem 60 mg) dans l'angor d'effort stable. Etude multicentrique а double insu contre placebo. Ann Cardiol Angeiol (Paris) 1995; 44: 203-12Manchanda S.C., Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-7Deroux A., Brochier M., Demange J. et al. Interкt therapeutique de l'association de la trimetazidine avec un inhibiteur calcique dans le traitement de l'insuffisance coronarienne chronique. Presse Med 1986; 15: 1783-7Szwed H., Pachocki R., Domzal-Bochenska M. et al. Efficacite et tolerance de la trimetazidine, antiangoreux metabolique, en association avec un antiangoreux hemodynamique dans l'angor d'effort stable. TRIMPOL I une etude multicentrique. Presse Med 2000; 29: 533-8Куимов А.Д., Маянская С.Д., Лукша Е.Б. и др. Влияние терапии триметазидином на толерантность к физической нагрузке и диастолическую функцию левого желудочка сердца у больных ишемической болезнью сердца. Тер Архив 1999; 71 (1): 39-42Guarnieri C., Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993; 46: 324-31Demaison L., Fantini E., Sentex E. et al. Trimetazidine: in vitro influence on heart mitochondrial function. Am J Cardiol 1995; 76: 31B-37BFantini E., Athias P., Demaison L. et al. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam Clin Pharmacol 1997; 11: 427-39Allibardi S., Chierchia S.L., Margonato V. et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovasc Drugs Ther 1998; 12: 543-9Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project - Free Radicals pilot study. Eur Heart J 1993; 14 (Suppl G): 48-51Meneveau N., Khalife K., Louis J. et al. Free radicals, thrombolytic therapy and myocardial infarction: results of the EMIP-FR angiography substudy. Eur Heart J 1997; 18: 171Effect of 48-h intravenous trimetazidine on short - and long - term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double - blind, placebo - controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Eur Heart J 2000; 21: 1537-46Di Pasquale P., Lo Verso P., Bucca V. et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short - term and long - term results. J Cardiovasc Drugs Ther 1999; 13: 423-8Papadopoulos C.L., Kanonidis I.E., Kotridis P.S. et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol 1996; 55: 137-42Пархоменко А.Е., Брыль З.В., Иркин О.И. и др. Применение антиоксиданта триметазидина (предуктал) в комплексной терапии острого инфаркта миокарда. Тер Архив 1996 68 (9) 47-52Ozdemir R., Tuncer C., Aladag M. et al. Effect of trimetazidine on late potentials after acute myocardial infarction. J Cardiovasc Drugs Ther 1999; 13: 145-9Birand A., Kudaiberdieva G.Z., Batyraliev T.A. et al. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997; 48: 413-22Ulgen M.S., Akdemir O., Toprak, N. The effects of trimetazidine on heart rate variability and signal - averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol 2001; 77: 255-62Drobinski G., Deroux A., Shutz D. Vie Med 1985; 9: 441-448.Venet R., Memin Y. Vie Med 1984; 8: 309-315.Brottier L., Barat J.L., Combe C. et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990; 11: 207-12Глезер М.Г., Соболев К.Э., Еремин Д.А. и др. Materia Medica 1997 №4.Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000; 19 (Suppl 5): V35-9Fabiani J.N., Ponzio O., Emerit I. et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992; 33: 486-91Tunerir B., Colak O., Alata_ O. et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999; 68: 2173-6Vedrinne J.M., Vedrinne C., Bompard D. et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double - blind, placebo - controlled study with trimetazidine. Anesth Analg 1996; 82: 712-8Kober G., Buck T., Sievert H. et al. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992 Aug; 13: 1109-15Steg P.G., Grollier G., Gallay P. et al. A randomized double - blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001; 77: 263-73Steg P.G., Grollier G., Gallay P. et al. A randomised double - blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Evidence for improved myocardial reperfusion from ST-segment analysis. Eur Heart J 1998; 19: 365Szwed H., Sadowski Z., Pachocki R. et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. J Cardiovasc Drugs Ther 1999; 13: 217-22Kozakiewicz K., Petelenz T., Chruciel T.L. Effectiveness of trimetazidine in patients with hypertension and the symptoms of coronary disease. Pol Tyg Lek 47 (27-28): 594-6Wierzbicki P., Cwetsch A., Fijakowski P. et al. Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end - stage renal failure patients treated by hemodialysis: preliminary communication. Pol Arch Med Wewn 1999; 102: 589-94.Szwed H., Pachocki R., Domzal-Bochenska N.I. et al. Efficacy and tolerance of trimetazidine in combination with a conventional antianginal drug in patients with stable effort angina. Diagn Treat Cardiol 1997; 4: 237-47Servier. Vastarel 20: a new strategic approach to the management of coronary artery disease. Servier. France.Jailon P. A bioequivalence study to compare the steady state pharmacokinetic profile of trimetazidine after a 4 day oral administration of 20 mg immediate release tablet and a 35 mg modified release tablet in 12 healthy volunteers. An open label randomised two - period cross - over study. Data on file.Sellier P. et al Assessment of the efficacy and safety of trimetazidine MR 35 mg (b.i.d. per os) in patients with stable angina pectoris and a positive exercise test despite treatment with a beta - blocker: Multicentre, double - blind, placebo - controlled study in two parallel groups. Cardiovasc Drugs Ther. 2001. 15 (suppl): 81Emeriau J.P. Clinical safety of trimetazidine MR 35 mg (b.i.d. per os) in 234 elderly patients (age 75 years) treated for one year: a double - blind placebo - controlled study with population pharmacokinetics. Data on file